IWAA 2018 21st Annual Scientific Session

Park City, UT US
July 19, 2018 to July 21, 2018

This meeting focuses on concerns and educational needs of allergists and immunologists.  Both national and regional thought leaders will provide an outstanding educational opportunity to all attendees.

Target Audience

Practicing allergists and allied healthcare providers in the field of allergy and immunology.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Summarize recent data, expert opinion and clinical practice guidelines on the treatment of allergic and immunological disease
  • Describe the safety and efficacy profiles of established and emerging therapies for the treatment of allergic and immunological diseases.
  • Apply knowledge of the pathophysiology of allergic and immunological diseases to clinical decision-making.

Funding

This activity is supported by independent educational grants from Aimmune, CLS Behring, Grifols, Kaleo.

 

 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.
William W. Busse, MD (Speaker): Advisory Board - ICON Clinical Research Limited; Consultant - AstraZeneca, Boehringer Ingelheim, Genentech, Novartis, Regeneron, Sanofi, Teva
Richard Henry, MD (Moderator): Principal Investigator - Sanofi, Genentech
Andrew MacGinnitie, MD, PhD (Speaker): Contracted Research - DBV Technologies
Jay Portnoy, MD (Speaker): Speaker - Boehringer Ingelheim, Thermo Fisher Scientific
Carl Thornblade, MD (Moderator): Contracted Research - Amphastar, AstraZeneca, Chiesi, Genentech, Novartis, Teva, 3M Health Care Ltd
Troy Torgerson, MD, PhD (Speaker): Advisory Board - CSL Behring, Grifols, Shire; Consultant: ADMA Biologics, CSL Behring, Shire

The following have no relevant financial relationships to disclose:
Ronald England, MD (Moderator)
Melissa Korenblat-Hanin, LCSW (Speaker)
Douglas Powell, MD (Speaker)
James Quinn, MD (Speaker)
Jim Thompson, PhD (Speaker)
Greg Wickern, MD (Moderator)
Doug Huneywell (Meeting Planner)

Course summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
Course opens: 
07/19/2018
Course expires: 
07/21/2020
Event starts: 
07/19/2018 - 4:30pm CDT
Event ends: 
07/21/2018 - 5:00pm CDT
Add to calendar: 
Rating: 
0
The Grand Summit Hotel
4000 Canyons Resort Drive
Park City, UT 84098
United States

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
Please login or create an account to take this course.